Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News INmune Bio Inc INMB

Healthcare Biotechnology
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to... see more

Recent & Breaking News (NDAQ:INMB)

INmune Bio, Inc. to Participate in January Investor Conferences and a Medical Meeting

GlobeNewswire January 4, 2022

INmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to be Presented at the 2021 San Antonio Breast Cancer Symposium

GlobeNewswire December 9, 2021

INmune Bio, Inc. Announces Two Presentations at the 2021 British Society of Immunology Congress and Provides 119-day data on First patient in MDS trial.

GlobeNewswire December 1, 2021

INmune Bio, Inc. Announces Third Quarter 2021 Results and Provides Business Update

GlobeNewswire November 3, 2021

INmune Bio, Inc. Announces Multiple Oral and Poster Presentations at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting

GlobeNewswire October 27, 2021

INmune Bio, Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, November 3

GlobeNewswire October 25, 2021

INmune Bio, Inc. to Participate in the B. Riley Fall 2021 Best Ideas in Oncology Series

GlobeNewswire September 27, 2021

INmune Bio, Inc. Announces Participation at Upcoming Investor Conferences

GlobeNewswire September 20, 2021

Alzheimer's Patients Treated with INmune Bio's XPro(TM) Show Reduction in CSF Phospho-Tau and Evidence of Remyelination

GlobeNewswire September 1, 2021

INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK Cell Priming "Pseudokine", INKmune(TM), Successfully Produced Memory-Like NK Cells

GlobeNewswire August 25, 2021

INmune Bio, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference

GlobeNewswire August 10, 2021

INmune Bio, Inc. to Present at the BTIG Virtual Biotechnology Conference

GlobeNewswire August 5, 2021

INmune Bio, Inc. Announces Second Quarter 2021 Results and Provides Business Update

GlobeNewswire August 4, 2021

INmune Bio, Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, August 4

GlobeNewswire July 28, 2021

INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer's Disease Clinical Trial and New Phase 1b AD Biomarker Data

GlobeNewswire July 26, 2021

INmune Bio acquires LUMICKS' z-Movi® Cell Avidity Analyzer to accelerate the development of its NK cell platform for cancer treatments

PR Newswire July 22, 2021

INmune Bio, Inc. Announces Poster Presentation and Plenary Talk at the Alzheimer's Association International Conference 2021

GlobeNewswire July 19, 2021

INMUNE BIO, INC. ANNOUNCES $40 MILLION REGISTERED DIRECT OFFERING

GlobeNewswire July 14, 2021

INmune Bio, Inc. Announces First Patient Treated with NK cell priming "pseudokine" INKmune in High-Risk Myelodysplastic Syndrome (MDS)

GlobeNewswire July 12, 2021

INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution

GlobeNewswire June 14, 2021